BioCardia, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>BioCardia, Inc. is holding its 2024 Annual Meeting on May 20, 2024, with a significant proposal for a reverse stock split.</b>

AI Summary

BioCardia, Inc. (BCDA) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Annual meeting scheduled for May 20, 2024, at 9:00 a.m. Pacific Time. Proposals include electing two Class II directors, ratifying PKF San Diego, LLP as independent auditor, and a non-binding vote on executive compensation. A key proposal is to approve an amendment for a reverse stock split of common stock, ranging from 1-for-2 to 1-for-20. If approved, the reverse stock split may also reduce authorized common shares from 100,000,000 to 50,000,000. The board of directors retains discretion to not effect the reverse stock split even if approved by stockholders.

Why It Matters

For investors and stakeholders tracking BioCardia, Inc., this filing contains several important signals. The proposed reverse stock split could significantly alter the company's share structure and potentially impact its stock price and market perception. Stockholders will vote on critical governance matters, including director elections and executive compensation, alongside the stock split proposal.

Risk Assessment

Risk Level: medium — BioCardia, Inc. shows moderate risk based on this filing. The company is proposing a reverse stock split, which can be a sign of financial distress or an attempt to meet exchange listing requirements, indicating potential underlying issues.

Analyst Insight

Stockholders should carefully consider the implications of the proposed reverse stock split and its potential impact on their investment before voting.

Key Numbers

• May 20, 2024 — Annual Meeting Date (2024 annual meeting of stockholders)
• 2 — Class II Directors (To elect two Class II directors)
• 2024 — Fiscal Year End (independent registered public accounting firm for our fiscal year ending December 31, 2024)
• 1-for-2 to 1-for-20 — Reverse Stock Split Ratio (reverse stock split of our issued common stock, at a ratio of 1-for-2 to 1-for-20)
• 100,000,000 — Current Authorized Shares (reduction in the number of authorized shares of common stock from 100,000,000 shares)
• 50,000,000 — Proposed Authorized Shares (to 50,000,000 shares)

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• May 20, 2024 (date) — Annual Meeting date
• PKF San Diego, LLP (company) — Independent registered public accounting firm
• 100,000,000 (dollar_amount) — Current authorized shares of common stock
• 50,000,000 (dollar_amount) — Proposed authorized shares of common stock

FAQ

Risk Factors

• Reverse Stock Split [medium — financial]: The company proposes a reverse stock split to potentially increase the per-share market price of its common stock, which may be a response to low stock prices or exchange listing requirements.

Industry Context

BioCardia, Inc. operates in the biotechnology sector, focusing on developing therapies for cardiovascular diseases.

Regulatory Implications

The filing is a Definitive Proxy Statement (DEF 14A) filed under the Securities Exchange Act of 1934, governing corporate governance and shareholder voting.

What Investors Should Do

1. Review the proxy statement thoroughly to understand all proposals, especially the reverse stock split.
2. Vote on the election of directors and the ratification of the independent auditor.
3. Consider the potential impact of the reverse stock split on share price and ownership dilution.

Key Dates

• 2024-05-20: Annual Meeting of Stockholders — Key date for voting on proposals, including director elections and a potential reverse stock split.

Year-Over-Year Comparison

This is a DEF 14A filing, indicating a proxy statement for an upcoming annual meeting, distinct from other filing types like 10-K or 10-Q.

Filing Documents

• bcda20240410_def14a.htm (DEF 14A) — 639KB
• a01.jpg (GRAPHIC) — 135KB
• a02.jpg (GRAPHIC) — 108KB
• peo.jpg (GRAPHIC) — 48KB
• tsr.jpg (GRAPHIC) — 47KB
• 0001437749-24-012080.txt (&nbsp;) — 1105KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 27 Fiscal 2023 Summary Compensation Table 28 Employment Agreements 28 Potential Payments on Termination or Change of Control 28 Outstanding Equity Awards at 2023 Year-End 29 Equity Compensation Plan Information 30

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 33 RELATED PERSON TRANSACTIONS 35 Policies and Procedures for Related Party Transactions 35 INCORPORATION BY REFERENCE 37 OTHER MATTERS 37 Delinquent Section 16(a) Reports 37 Fiscal Year 2023 Annual Report and SEC Filings 37 ANNEX A – Certificate of Amendment A-1 BIOCARDIA, INC. PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 9:00 a.m. Pacific Time on Monday, May 20, 2024 This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at the 2024 annual meeting of stockholders of BioCardia, Inc., a Delaware corporation, or BioCardia, the Company, we, our, or us, and any postponements, adjournments or continuations thereof, or the Annual Meeting. The Annual Meeting will be held on Monday, May 20, 2024 at 9:00 a.m. Pacific Time, at Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304-1050. Our proxy materials are first being mailed on or about April 16, 2024 to all stockholders entitled to notice of and to vote at the Annual Meeting. The information provided in the "question and answer" format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read this entire proxy statement carefully. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this proxy statement and references to our website address in this proxy statement are inactive textual references only. This Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are available on the Financials & Filings portion of our website at www.biocardia.com/investors/financials-filings/id/1021 . What matters am I voting on? You will be voting on: the election of two Class II directors to serve until the 2027 annua

View Full Filing

View this DEF 14A filing on SEC EDGAR